Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Basu

Gynecologic oncology

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Gynecologic Oncology|February 1, 2006
A study to evaluate the use of CA125 in ovarian cancer follow-up: A change in practice led by patient preferenceCheryl Palmer, Jennie Pratt, Bristi Basu, et al.
Gynecologic Oncology|October 1, 1994
Lipid-soluble antioxidants: beta-carotene and alpha-tocopherol levels in breast and gynecologic cancersP R Palan, G L Goldberg, J Basu, et al.
Gynecologic Oncology|November 6, 2003
Problems in reporting doses and volumes during multiple high-dose-rate intracavitary brachytherapy for carcinoma cervix as per ICRU Report 38: a comparative study using flexible and rigid applicatorsNiloy R Datta, Rimpa Basu, Koilpillai J M Das, et al.
Gynecologic Oncology|January 1, 1985
Chemoprevention of cervix cancer: Phase I-II: A feasibility study involving the topical vaginal administration of retinyl acetate gelS L Romney, A Dwyer, S Slagle, et al.
Gynecologic Oncology|August 20, 2010
RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cellsShilpi Arora, Kristen M Bisanz, Lourdes A Peralta, et al.
Gynecologic Oncology|September 14, 2011
Genetic and epigenetic changes of HPV16 in cervical cancer differentially regulate E6/E7 expression and associate with disease progressionDipanjana Mazumder Indra, Ratnesh Kumar Singh, Sraboni Mitra, et al.
Gynecologic Oncology|June 1, 1997
Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infectionS L Romney, G Y Ho, P R Palan, et al.
Gynecologic Oncology|October 30, 2021
Increasing global accessibility to high-level treatments for cervical cancersC Chargari, M Arbyn, A Leary, et al.
Gynecologic Oncology|May 8, 2024
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 studyAntonio González-Martín, Hyun Cheol Chung, Esma Saada-Bouzid, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Gynecologic Oncology|February 1, 2006
A study to evaluate the use of CA125 in ovarian cancer follow-up: A change in practice led by patient preferenceCheryl Palmer, Jennie Pratt, Bristi Basu, et al.
Gynecologic Oncology|October 1, 1994
Lipid-soluble antioxidants: beta-carotene and alpha-tocopherol levels in breast and gynecologic cancersP R Palan, G L Goldberg, J Basu, et al.
Gynecologic Oncology|November 6, 2003
Problems in reporting doses and volumes during multiple high-dose-rate intracavitary brachytherapy for carcinoma cervix as per ICRU Report 38: a comparative study using flexible and rigid applicatorsNiloy R Datta, Rimpa Basu, Koilpillai J M Das, et al.
Gynecologic Oncology|January 1, 1985
Chemoprevention of cervix cancer: Phase I-II: A feasibility study involving the topical vaginal administration of retinyl acetate gelS L Romney, A Dwyer, S Slagle, et al.
Gynecologic Oncology|August 20, 2010
RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cellsShilpi Arora, Kristen M Bisanz, Lourdes A Peralta, et al.
Gynecologic Oncology|September 14, 2011
Genetic and epigenetic changes of HPV16 in cervical cancer differentially regulate E6/E7 expression and associate with disease progressionDipanjana Mazumder Indra, Ratnesh Kumar Singh, Sraboni Mitra, et al.
Gynecologic Oncology|June 1, 1997
Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infectionS L Romney, G Y Ho, P R Palan, et al.
Gynecologic Oncology|October 30, 2021
Increasing global accessibility to high-level treatments for cervical cancersC Chargari, M Arbyn, A Leary, et al.
Gynecologic Oncology|May 8, 2024
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 studyAntonio González-Martín, Hyun Cheol Chung, Esma Saada-Bouzid, et al.
Pageof 1